Loading…
DiaMedica Therapeutics Inc. is projected to rise to $7.04 by 2027, a +11% move from its current price of $6.34. DMAC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $6.17 | $6.34 | $6.51 | +0.03% |
| Aug 4 | $6.11 | $6.34 | $6.59 | +0.05% |
| Aug 5 | $6.06 | $6.34 | $6.65 | +0.08% |
| Aug 6 | $6.01 | $6.35 | $6.70 | +0.10% |
| Aug 7 | $5.98 | $6.35 | $6.74 | +0.13% |
| Aug 8 | $5.94 | $6.35 | $6.78 | +0.16% |
| Aug 9 | $5.91 | $6.35 | $6.82 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.91 | $6.35 | $6.82 | +0.18% |
| Week 2 | $5.75 | $6.36 | $7.04 | +0.36% |
| Week 3 | $5.63 | $6.37 | $7.21 | +0.55% |
| Week 4 | $5.54 | $6.39 | $7.36 | +0.73% |
| Week 5 | $5.46 | $6.40 | $7.50 | +0.91% |
| Week 6 | $5.38 | $6.41 | $7.63 | +1.09% |
| Week 7 | $5.32 | $6.42 | $7.75 | +1.28% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on improving the lives of people suffering from severe ischemic diseases.
Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DiaMedica Therapeutics Inc. (DMAC) is a healthcare company currently trading at $6.32 per share.
Its market cap is $340.54M and it ranks 3368 by market cap.
The forecast implies an initial flat 2026, with min $5.33, avg $6.32, max $7.86 and ROI 0, sentiment NEUTRAL.
Over the longer horizon, the avg price is projected to rise to $10.03 by 2030 with ROI 58.7% and to $45.87 by 2050 with ROI 625.7%, underscoring a bullish long-term trend.
A major floor 27.9% below — a decisive break under it would weaken the trend.
The nearest floor, 7.7% below — buyers have tended to step in here.
The nearest ceiling, 26.3% above — a clean break opens room to run.
A major ceiling 40.3% above — clearing it would confirm fresh momentum.
Key DMAC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DMAC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.51 | Sell | $6.51 | Sell |
| MA 10 | $6.71 | Sell | $6.69 | Sell |
| MA 20 | $7.17 | Sell | $6.83 | Sell |
| MA 50 | $6.50 | Sell | $6.72 | Sell |
| MA 100 | $6.53 | Sell | $6.74 | Sell |
| MA 200 | $7.20 | Sell | $6.69 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.60 | Neutral |
| Stoch RSI (14) | 6.85 | Buy |
| CCI (20) | -119.61 | Sell |
| Williams %R (14) | -98.48 | Info |
| MACD (12,26,9) | -0.15 | Sell |
| ROC (12) | -17.02 | Sell |
| Bollinger %B (20,2) | 0.11 | Neutral |
| Stochastic %K (14) | 1.52 | Buy |
| TRIX (15) | 0.23 | Buy |
| Awesome (5,34) | -0.33 | Sell |
| Ultimate (7,14,28) | 26.56 | Buy |
| Momentum (10) | -0.96 | Sell |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 6.32 | Buy |
| ADX (14) | 18.93 | Neutral |
| ATR (14) | 0.18 | Info |
The 30-day technical picture is NEUTRAL. RSI(14) is 40, with the 50-day simple moving average at $6.47 and the 200-day simple moving average at $7.20. The stock shows a near-term support at $5.69 and resistance at $8.01. The 30-day trading range spans from $5.28 to $7.57, and annualized volatility stands at 50%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.33 | $6.34 | $7.87 | 0% | Neutral | |
| $5.62 | $7.04 | $9.31 | +11% | Neutral | |
| $5.64 | $7.26 | $9.96 | +14% | Neutral | |
| $5.97 | $7.86 | $11.11 | +24% | Bullish | |
| $7.27 | $9.77 | $14.16 | +54% | Bullish | |
| $8.13 | $11.13 | $16.46 | +76% | Bullish | |
| $8.82 | $12.29 | $18.53 | +94% | Bullish | |
| $9.45 | $13.38 | $20.52 | +111% | Bullish | |
| $9.43 | $13.56 | $21.12 | +114% | Bullish | |
| $9.57 | $13.96 | $22.07 | +120% | Bullish | |
| $14.46 | $22.53 | $37.87 | +255% | Bullish | |
| $24.90 | $43.43 | $79.84 | +585% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $5.33 | $6.34 | $7.48 | +0.00% |
| September 2026 | $5.31 | $6.28 | $7.63 | -1.01% |
| October 2026 | $5.45 | $6.49 | $7.97 | +3.44% |
| November 2026 | $5.41 | $6.48 | $8.02 | -0.24% |
| December 2026 | $5.24 | $6.30 | $7.87 | -2.66% |
Click any year to see its month-by-month DMAC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect DMAC to range from $5.33 to $7.87 through 2026. The $6.34 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The DMAC price prediction for 2027 points to an average of $7.04 (low $5.62, high $9.31) — a potential gain of +11% on today's $6.34. A consolidation phase looks the most probable path here.
In 2028, DMAC is projected to trade between $5.64 and $9.96, averaging $7.26 — a potential gain of +14% from today's $6.34. That is up +3% on the projected 2027 average. Price action looks broadly range-bound.
DiaMedica Therapeutics Inc.'s 2029 outlook centres on $7.86, within a $5.97 to $11.11 range. That is up +8% on the projected 2028 average. That marks a +24% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, DMAC could reach as high as $14.16, with a base case around $9.77 and support toward $7.27 — roughly +54% from $6.34. Momentum favours further upside here.
Expect DMAC to range from $8.13 to $16.46 through 2031. The $11.13 average target implies a +76% move from current prices. That is up +14% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The DMAC price prediction for 2032 points to an average of $12.29 (low $8.82, high $18.53) — a potential gain of +94% on today's $6.34. Momentum favours further upside here.
In 2033, DMAC is projected to trade between $9.45 and $20.52, averaging $13.38 — a potential gain of +111% from today's $6.34. That is up +9% on the projected 2032 average. Buyers look set to stay in control over this stretch.
DiaMedica Therapeutics Inc.'s 2034 outlook centres on $13.56, within a $9.43 to $21.12 range. That is up +1% on the projected 2033 average. That marks a +114% change versus current levels. Momentum favours further upside here.
By 2035, DMAC could reach as high as $22.07, with a base case around $13.96 and support toward $9.57 — roughly +120% from $6.34. Buyers look set to stay in control over this stretch.
Expect DMAC to range from $14.46 to $37.87 through 2040. The $22.53 average target implies a +255% move from current prices. That is up +61% on the projected 2035 average. Momentum favours further upside here.
The DMAC price prediction for 2050 points to an average of $43.43 (low $24.90, high $79.84) — a potential gain of +585% on today's $6.34. Buyers look set to stay in control over this stretch.
Investing $1,000 in DMAC today (≈ 157.728707 DMAC) could be worth
$6,850.93
+$5,850.93 (+585%) by 2050 · US Dollar
Based on the average projected DMAC price of $43.43 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DMACwould be worth at today's price.
$1,000 invested in DMAC on Jul 31, 2025 (≈ 236.966836 DMAC) would be worth
$1,502.37
+$502.37 (+50.2%) today · 1.50× · US Dollar
Based on a DMAC entry price of $4.22 vs. today's $6.34.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.74 | $941.35 | -5.9% |
| 1 month ago | $7.44 | $852.15 | -14.8% |
| 3 months ago | $6.18 | $1,025.89 | +2.6% |
| 6 months ago | $8.18 | $775.06 | -22.5% |
| 1 year ago | $4.22 | $1,502.37 | +50.2% |
| All time (5.0y) ago | $3.31 | $1,915.41 | +91.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DMAC forecast.
Our base-case forecast reaches $13.00 around 2033.
Implied market cap at $13.00: $700.48M
The multi-year forecast shows a bullish trajectory, with the average price rising from $7.97 in 2029 (ROI 26.1) to $10.03 in 2030 (ROI 58.7). It then climbs through 2031 ($11.38, ROI 80.1), 2032 ($12.61, ROI 99.6), 2033 ($13.82, ROI 118.7), 2034 ($13.91, ROI 120.2), and 2035 ($14.40, ROI 127.8).
By 2040, the average price is projected at $23.43 with a max of $39.59 and ROI of 270.7. By 2050, the average price is $45.87 with a max of $84.83 and ROI of 625.7. These figures reflect an overall bullish stance, though they are estimates and not guarantees, and actual results may differ.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $10.03 per share and an ROI of 58.7%. The 2030 range is min $7.44 and max $14.58.
The forecast shows a rising average price over time, with 2027 avg $7.08 ROI 12.1 and 2050 avg $45.87 ROI 625.7. These are estimates and not guarantees.
Yes. The 2050 max forecast is $84.83, which would exceed $50.
Current price is $6.32 and market cap is $340.54M.
Sentiment is NEUTRAL. RSI(14) is 40. The 50-day SMA is $6.47 and the 200-day SMA is $7.20. Support is at $5.69 and resistance at $8.01. The 30-day range is $5.28 to $7.57, and annualized volatility is 50%.
DiaMedica Therapeutics Inc. Community Discussion
0Share your DiaMedica Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.